ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2005
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 52 citations in OpenAlex.
- Frailty and Cardiovascular Risk.European cardiology · 2026Review
- Article
- A comparison of synthetic data generation and federated analysis for enabling international evaluations of cardiovascular health.Scientific reports · 2023Article
- Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.Molecular medicine reports · 2020Article
- Development of reusable logic for determination of statin exposure-time from electronic health records.Journal of biomedical informatics · 2014Article
- Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database.Pharmacoepidemiology and drug safety · 2014Article
- Review
- Incomparable effectiveness--apples to apples?Mayo Clinic proceedings · 2010Article
- Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.European journal of clinical pharmacology · 2009Article
- Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Review
- Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007Article
- Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.Heart (British Cardiac Society) · 2007Article
- Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?The Canadian journal of cardiology · 2007Article
- Impact of adherence to statins on coronary artery disease in primary prevention.British journal of clinical pharmacology · 2007Article
- Sex differences in the effectiveness of statins after myocardial infarction.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2007Article
- Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2007Article
- Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.Clinical drug investigation · 2007Review
- An evaluation of class effect.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2006Article
- Statins research unfinished saga: desirability versus feasibility.Cardiovascular diabetology · 2005Article
- Are the benefits of statins a class effect?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2005Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials have shown the benefits of statins after acute myocardial infarction (AMI). However, it is unclear whether different statins exert a similar effect in reducing the incidence of recurrent AMI and death when used in clinical practice.
methodsWe conducted a retrospective cohort study (1997-2002) to compare 5 statins using data from medical administrative databases in 3 provinces (Quebec, Ontario and British Columbia). We included patients aged 65 years and over who were discharged alive after their first AMI-related hospital stay and who began statin treatment within 90 days after discharge. The primary end point was the combined outcome of recurrent AMI or death from any cause. The secondary end point was death from any cause. Adjusted hazard ratios (HRs) for each statin compared with atorvastatin as the reference drug were estimated using Cox proportional hazards regression analysis.
resultsA total of 18,637 patients were prescribed atorvastatin (n = 6420), pravastatin (n = 4480), simvastatin (n = 5518), lovastatin (n = 1736) or fluvastatin (n = 483). Users of different statins showed similar baseline characteristics and patterns of statin use. The adjusted HRs (and 95% confidence intervals) for the combined outcome of AMI or death showed that each statin had similar effects when compared with atorvastatin: pravastatin 1.00 (0.90-1.11), simvastatin 1.01 (0.91-1.12), lovastatin 1.09 (0.95-1.24) and fluvastatin 1.01 (0.80-1.27). The results did not change when death alone was the end point, nor did they change after adjustment for initial daily dose or after censoring of patients who switched or stopped the initial statin treatment.
interpretationOur results suggest that, under current usage, statins are equally effective for secondary prevention in elderly patients after AMI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.